HLB TherapeuticsLtd Balance Sheet Health
Financial Health criteria checks 6/6
HLB TherapeuticsLtd has a total shareholder equity of ₩171.5B and total debt of ₩9.3B, which brings its debt-to-equity ratio to 5.4%. Its total assets and total liabilities are ₩200.8B and ₩29.3B respectively.
Key information
5.4%
Debt to equity ratio
₩9.28b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩32.35b |
| Equity | ₩171.52b |
| Total liabilities | ₩29.28b |
| Total assets | ₩200.79b |
Recent financial health updates
Recent updates
HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 38% Share Price Surge Not Quite Adding Up
Apr 11
There's Reason For Concern Over HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Massive 50% Price Jump
Feb 26Does G-treeBNT (KOSDAQ:115450) Have A Healthy Balance Sheet?
Mar 19Did Business Growth Power G-treeBNT's (KOSDAQ:115450) Share Price Gain of 134%?
Dec 21
Financial Position Analysis
Short Term Liabilities: A115450's short term assets (₩49.8B) exceed its short term liabilities (₩26.8B).
Long Term Liabilities: A115450's short term assets (₩49.8B) exceed its long term liabilities (₩2.5B).
Debt to Equity History and Analysis
Debt Level: A115450 has more cash than its total debt.
Reducing Debt: A115450's debt to equity ratio has reduced from 10.9% to 5.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A115450 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A115450 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 2.6% each year